Anika Therapeutics (ANIK) Tops Q2 EPS by 35c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $20.38 +4.78%
EPS Growth %: +950.0%
Financial Fact:
Product revenue: 25.78M
Today's EPS Names:
ATS, SICP, FTCO, More
EPS Growth %: +950.0%
Financial Fact:
Product revenue: 25.78M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.68, $0.35 better than the analyst estimate of $0.33. Revenue for the quarter came in at $30.5 million versus the consensus estimate of $27.9 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- Scotts Miracle-Gro (SMG) Tops Q4 EPS by 5c ; Offers Guidance
- McDonald's posts better-than-expected third-quarter comparable sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
